Published papers
Academic conference presentation
    （Last updated : 2026-01-16 15:22:48）
  NAKAYAMA Takayuki
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine  Department of Urology
   Position   Assistant Professor
■ Published papers
1. Original article　 Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
2. Original article　 Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
3. Case report　 Safety of enfortumab vedotin plus pembrolizumab in hemodialysis patients with metastatic urothelial carcinoma: Case report 2025/09/01
4. Original article　 Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2025/09
5. Original article　 Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
Display all(10)
■ Academic conference presentation
1. Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （Poster notice，General） 2025/09/26
2. Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. （Poster notice，General） 2025/04/27
3. Primary renal tumor response in patients treated with first-line systemic therapy for advanced renal cell carcinoma. （Poster notice，General） 2024/04/26